Hyperkalemia due to nafamostat mesylate
H Kitagawa, H Chang, T Fujita - New England Journal of …, 1995 - Mass Medical Soc
H Kitagawa, H Chang, T Fujita
New England Journal of Medicine, 1995•Mass Medical SocTo the Editor: Nafamostat mesylate (6-amidino-2-naphthyl p-guanidinobenzoate,
dimethanesulfonate; molecular weight, 540) is a synthetic serine protease inhibitor that is
widely used to treat acute pancreatitis in Japan. 1 The drug and its metabolites reversibly
inhibit amiloride-sensitive sodium conductance of renal cortical collecting ducts, 2, 3 thus
impairing urinary potassium excretion. Hyperkalemia could therefore develop in patients
receiving this drug. We describe a 77-year-old man admitted to the hospital for acute …
dimethanesulfonate; molecular weight, 540) is a synthetic serine protease inhibitor that is
widely used to treat acute pancreatitis in Japan. 1 The drug and its metabolites reversibly
inhibit amiloride-sensitive sodium conductance of renal cortical collecting ducts, 2, 3 thus
impairing urinary potassium excretion. Hyperkalemia could therefore develop in patients
receiving this drug. We describe a 77-year-old man admitted to the hospital for acute …
To the Editor: Nafamostat mesylate (6-amidino-2-naphthyl p-guanidinobenzoate, dimethanesulfonate; molecular weight, 540) is a synthetic serine protease inhibitor that is widely used to treat acute pancreatitis in Japan.1 The drug and its metabolites reversibly inhibit amiloride-sensitive sodium conductance of renal cortical collecting ducts,2,3 thus impairing urinary potassium excretion. Hyperkalemia could therefore develop in patients receiving this drug.
We describe a 77-year-old man admitted to the hospital for acute pancreatitis in whom nafamostat mesylate therapy was associated with hyperkalemia. The patient was initially treated with intravenous fluids and a continuous infusion of nafamostat mesylate (150 mg per day). The intravenous . . .
The New England Journal Of Medicine